%0 Journal Article
%T Long-term survival after intraperitoneal chemotherapy with paclitaxel-cisplatin for recurrent primary peritoneal cancer resistant to multiple lines of intravenous chemotherapy
%A Dong Hoon Suh
%A Hyejeong Hue
%A HyoJin Kim
%A Jae Hong No
%A Kidong Kim
%A Yong Beom Kim
%J Archive of "Obstetrics & Gynecology Science".
%D 2019
%R 10.5468/ogs.2019.62.4.285
%X The long-term survival of heavily pretreated patients with primary peritoneal cancer (PPC) is uncommon. Here, we report on a patient with PPC refractory to multiple lines of intravenous chemotherapy, namely, a combined regimen of paclitaxel and carboplatin, and single regimens of topotecan, docetaxel, cisplatin, and gemcitabine. However, after intraperitoneal (IP) chemotherapy with paclitaxel-cisplatin, the patient's condition improved, and she has been progression-free for more than 4 years. Interestingly, before the IP chemotherapy, the recurrences were limited to the peritoneal cavity. These results suggest that IP recurrence might be a predictor of a good response to IP chemotherapy
%K Peritoneal neoplasms
%K Neoplasm recurrence
%K local
%K Infusions
%K parenteral
%K Drug therapy
%K Ovarian neoplasms
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6629981/